CTOs on the Move

Virtual Incision

www.virtualincision.com

 
Virtual Incision Corporation is a privately-held medical device company focused on developing an advanced, miniaturized robot for general surgery abdominal procedures, such as colon resections. Propelled by the knowledge that colorectal and lower gastrointestinal procedures are the fastest growing in the United States, Dr. Dmitry Oleynikov and Dr. Shane Farritor founded Virtual Incision in 2006. The company is a spin-out of the University of Nebraska, where Dr. Dmitry Oleynikov and Dr. Shane Farritor are currently based. John Murphy joined Virtual Incision in 2012 and is based in Pleasanton, California.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Shane Farritor
 Chief Technology Officer Profile

Funding

Virtual Incision raised $11.2M on 08/06/2015
Virtual Incision raised $18M on 12/12/2017
Virtual Incision raised $20M on 01/08/2020

Similar Companies

Cannalysis Labs

Cannalysis was founded in 2015, in Costa Mesa CA. Initially, Cannalysis exclusively served Southern California with a limited amount of analyses available. As the operational and testing requirements expanded, Cannalysis moved its headquarters to a 12,000 sqft state-of-the-art facility in Santa Ana, CA.

Expansion Therapeutics

Expansion Therapeutics is a drug discovery and development company pursuing the vast potential of small molecule medicines for RNA-mediated diseases.

ROME Therapeutics

ROME Therapeutics is developing novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome – vast stretches of uncharted genetic material that have long been dismissed as “junk DNA.”

Piedmont Medical Laboratory

Piedmont Medical Laboratory is a Winchester, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Jasper Therapeutics

Jasper Therapeutics is a biotechnology company on a mission to make safer and potentially curative therapy possible for more patients in need. We are bringing together a team of biotech veterans, leading academic institutions and a strong syndicate of healthcare-focused investors to achieve our vision of developing new therapies for diseases of mast and stem cells, and safer and more effective conditioning for monogenetic diseases.